Abstract | In addition to long-term regulation of angiogenesis, angiogenic growth factor signalling through nitric oxide (NO) acutely controls blood flow and haemostasis. Inhibition of this pathway may account for the hypertensive and pro-thrombotic side effects of the vascular endothelial growth factor antagonists that are currently used for cancer treatment. The first identified endogenous angiogenesis inhibitor, thrombospondin 1, also controls tissue perfusion, haemostasis and radiosensitivity by antagonizing NO signalling. We examine the role of these and other emerging activities of thrombospondin 1 in cancer. Clarifying how endogenous and therapeutic angiogenesis inhibitors regulate vascular NO signalling could facilitate development of more selective inhibitors.
The insight that tumour growth requires angiogenesis led to the development and clinical use of angiogenesis inhibitors as cancer therapeutics. The drugs bevacizumab, sorafenib and sunitinib, which are approved by the US Food and Drug Administration for the treatment of several cancers, act specifically or in part by blocking the angiogenic activity of the vascular endothelial growth factor (Vegf) pathway. These targeted drugs significantly extend the survival of cancer patients but have cardiovascular side effects that include hypertension and thrombosis [1] [2] [3] . Although most attempts to define the aetiology of their hypertensive activity have focused on long-term changes in vessel architecture, VEGFA signalling through nitric oxide (NO) also has acute effects on vessel tone 4, 5 , and hypertension induced by the experimental Vegf receptor kinase inhibitor cediranib was recently shown to be caused by acute disruption of NO synthesis in vascular endothelium 6 . Recent studies of the first identified endogenous angiogenesis inhibitor, thrombospondin 1 (TSP1), reveal that it also inhibits NO-mediated signalling to acutely control tissue perfusion and haemostasis 7, 8 . Interestingly, the pioneering work of Folkman and colleagues showed that tumours can produce circulating angiogenesis inhibitors 9 , and circulating TSP1 levels are increased in people and mice with certain cancers [10] [11] [12] . The benefit to the tumour of circulating angiogenesis inhibitors, which in some cases are produced by stromal rather than tumour cells, is unclear. We propose that increased plasma TSP1 can enhance tumour perfusion through its hypertensive activity. This Review synthesizes emerging evidence that haemostasis and tissue blood flow are acute targets of both endogenous and therapeutic angiogenesis inhibitors and explores ways that this insight can be used to improve anti-angiogenic therapy.
Nitric oxide
Physiological activity of NO was first described by Davy in 1800 (Ref. 13 ), but its production by mammalian tissues and its role as a signalling molecule in vascular cells were not discovered until the 1980s (Ref. 14) . The primary endogenous source of NO in endothelial cells is the endothelial isoform of nitric oxide synthase (eNOS, also known as NOS3). NOS3 is a highly regulated enzyme that is controlled by varying its expression, post-translational modification, subcellular localization and binding of several regulatory proteins 15 . NO diffuses rapidly through tissue and across cell membranes and binds to its most sensitive known target, soluble guanylate cyclase (sGC), to stimulate the production of cyclic GMP 16 , which regulates a number of signalling pathways that affect vascular cell function (fIG. 1a) . NO at low concentrations promotes vascular cell survival, proliferation and migration. Higher levels of NO trigger additional signalling pathways directly or following conversion to other reactive nitrogen species 17 , but the control of NO signalling in vascular cells appears to be specific for the NO-cGMP pathway, and thus this pathway is the focus of this Review 18 .
Hypertension
A condition in which blood pressure is chronically increased.
Thrombosis
formation of a blood clot (thrombus) inside a blood vessel that obstructs blood flow.
Vessel tone
An assessment of vessel resistance to blood flow. Vessel tone is decreased by NO-mediated vasodilation and increased by activity of autonomic innervation and the presence of vasopressors.
Tissue perfusion
The volume of blood that flows through a unit quantity of tissue.
Haemostasis
The physiological process that arrests bleeding at a site of injury by formation of a haemostatic plug, resolves this plug during healing and maintains circulating blood in a fluid state in the absence of injury.
Nitric oxide synthase
Mammalian genomes encode three nitric oxide synthases: NOS1 (nNOS) is constitutively expressed in neuronal tissues, NOS2 (iNOS) is an inducible enzyme in phagocytic cells that can also be induced by inflammatory mediators in vascular cells, and NOS3 (eNOS) is a constitutively expressed but highly regulated enzyme in endothelium and platelets.
Mechanical shear
A physical force exerted on endothelial cells in blood vessels as a result of blood flow, which regulates the activity of NOS3 in endothelium.
In the cardiovascular system NO-cGMP signalling has several important physiological functions (fIG. 1a) . NO produced by endothelium diffuses into the vessel wall and relaxes vascular smooth muscle cells (VSMCs) in arteries, thereby increasing vessel diameter, lowering resistance and enhancing blood flow to tissues. Endothelial cell-derived NO thereby mediates acute local self-regulation of arterial tone in response to changes in mechanical shear sensed by the endothelium and to circulating factors such as VEGFA or acetylcholine. NO also diffuses into the lumen of vessels, where it regulates haemostasis by limiting platelet aggregation 19 . Finally, NO acts in an autocrine manner to regulate endothelial permeability and angiogenesis 20 . These vascular responses to NO occur over different timescales (fIG. 1b) . Haemostasis and vessel tone are regulated acutely, whereas angiogenesis requires a sustained increase of NO levels.
Angiogenic factors stimulate NO synthesis NO-cGMP signalling is required for angiogenesis in tumour and wound healing environments, and several angiogenesis factors stimulate this signalling node 20 . VEGFA activates NOS3 through several pathways (fIG. 1c) . The key role of NOS3 in VEGFA signalling is supported by deficiencies in both angiogenesis and acute permeability responses to VEGFA in Nos3-null mice 21 . Angiogenic responses to angiopoietin 1 and angiopoietin-related protein 1 are similarly deficient in Nos3-null mice 22, 23 . Pro-angiogenic signalling by adrenomedullin, oestrogens, insulin, lysophosphatidic acid, sphingosine-1-phosphate and fibroblast growth factor 2 (FGF2) also involve NO 15, [24] [25] [26] . Therefore, the NO-cGMP pathway is an important signalling node for a number of angiogenic factors.
Because of its important role in tumour angiogenesis, inhibition of NOS3 has been considered as an approach to inhibit tumour growth. Accordingly, tumour growth rates and angiogenesis decrease in animals treated with NOS inhibitors 27 , and angiogenesis and metastasis correlate with the level of NOS3 expression 28 . However, NO also has stimulatory and inhibitory roles in antitumour immunity 29 . Inhibiting NOS delayed immune rejection of tumours 30 , and stromal cell production of NO suppressed growth 31 . Therefore, general inhibition of NOS might not be an effective strategy to control tumour growth. At higher levels, NO is metabolized into reactive nitrogen species that have enhanced cytotoxic activities 32 .
What limits physiological NO signalling?
Whereas the downstream biochemical and physiological targets of NO that mediate its positive effects on vascular cells are well understood, less attention has been given to negative regulation of NO-cGMP signalling. The distance NO diffuses in vascular tissues and the duration of its signalling are limited by its binding to haemcontaining proteins, especially to the abundant haemoglobin in red blood cells 33 . NO bound to haemoglobin is converted to nitrite, which serves as a reservoir to regenerate NO under hypoxic conditions, such as occur in solid tumours 33 . NO is metabolized to reactive nitrogen species, and these can react with protein thiols or glutathione to form adducts that can regenerate nitrite or NO 34 . In certain tissues a family of cGMP phosphodiesterases is important for limiting NO signalling by degrading the product of NO-driven sGC activation 35 . However, the sustained physiological activity of inhaled NO 36, 37 , the limited ability of phosphodiesterase inhibitors to dramatically alter blood pressure 38,39 and the number of major human diseases associated with states of socalled NO insufficiency of undefined origin 40,41 provide compelling evidence that additional regulatory pathways must limit NO-cGMP signalling. One of these pathways is mediated by the secreted protein TSP1.
TSP1 blocks NO-driven angiogenesis
The thrombospondin family comprises five secreted proteins that have distinct roles in development and physiology 42 . TSP3, TSP4 and COMP (cartilage oligomeric matrix protein, also known as TSP5) are pentameric proteins that are most abundant in bone and cartilage extracellular matrix. Specific mutations in COMP cause two inherited forms of dwarfism 43 . To date, associations of TSP3, TSP4 and COMP with cancer are limited to isolated reports of altered expression [44] [45] [46] [47] [48] [49] . TSP1 and TSP2 constitute a subfamily of trimeric TSPs, and both are angiogenesis inhibitors 50 . TSP1 is the most abundant protein in α-granules of platelets, from which it is rapidly released during haemostasis 51 . Platelets may also serve as a buffer to control circulating TSP1
At a glance
• Nitric oxide (NO) mediates pro-angiogenic activities of vascular endothelial growth factor A (VEGFA) and a number of additional angiogenic factors that support the neovascularization of tumours. This signalling involves activation of soluble guanylate cyclase and downstream targets of cyclic GMP.
• Thrombospondin 1 (TSP1) and TSP2 are endogenous angiogenesis inhibitors. Their expression is frequently lost during cancer progression, and overexpression suppresses tumour growth. TSP1 is a potent antagonist of NO signalling in vascular endothelial cells, vascular smooth muscle cells and platelets. TSP2 is substantially less active.
• Antagonism of NO signalling can be mediated by TSP1 binding to two of its receptors, CD36 and CD47. CD47 mediates inhibition at much lower concentrations of TSP1, and CD47 is also required for signalling through CD36.
• TSP1 signalling through CD47 redundantly inhibits NO signalling at the level of soluble guanylate cyclase and cGMP-dependent protein kinase.
• In addition to long-term inhibition of angiogenesis, antagonism of NO signalling by TSP1 results in acute inhibition of tissue perfusion and acceleration of platelet haemostasis. Consequently, TSP1 and CD47 limit recovery of blood flow and tissue survival following ischaemic injuries. By contrast, tumour vasculature is resistant to acute vasodilation by NO, and increased circulating TSP1 produced by tumour stroma may instead indirectly increase tumour perfusion by limiting blood flow elsewhere.
• These activities of TSP1 parallel the hypertensive and pro-thrombotic activities that are emerging as frequent side effects of therapeutic angiogenesis inhibitors, and both can be explained by inhibition of NO signalling.
• TSP1 signalling through CD47 also limits soft tissue survival after radiation injury. Disruption of this pathway is a possible strategy to permit delivery of higher therapeutic radiation doses to tumours while selectively protecting surrounding healthy tissues. . TSP2 is not found in platelets but is expressed by other vascular cells. Polymorphisms in THBS1 and THBS2, which encode TSP1 and TSP2, have been associated with increased risk of cardiovascular disease [54] [55] [56] but not with cancer to date 57 . Altered TSP1 and/or TSP2 expression has been observed in a number of human and murine cancers (for examples see TABLe 1) . TSP1 expression in many human cancers is inversely correlated with progression, and in a few cases was found to be an independent prognostic indicator 58, 59 . One of the more consistent inverse relationships has been observed in colon cancer 60 . However, lack of correlation with progression and a few positive correlations have also been reported. 61 . Careful examination of some tumours that showed a positive correlation, however, revealed that the increased TSP1 originated not from tumour cells but rather from stromal cells in the tumour [62] [63] [64] . Induction of stromal TSP1 expression appears to be a paracrine effect of growth factors released by tumour cells. Studies of chemical-induced and spontaneous carcinogenesis in TSP1 or TSP2 transgenic mice support the hypothesis that paracrine induction of TSP1 and TSP2 expression has an important inhibitory role in tumour progression 65, 66 . loss of expression in cancers does not result from mutation or deletion of THBS1 and THBS2, so these are not classic tumour suppressors. Rather, expression is lost owing to epigenetic silencing through hypermethylation 59, 67, 68 or decreased by loss of positive regulation by tumour suppressors such as p53 (Ref. 69) or gain of negative regulation by oncogenes such as Ras, ID1 and MYC [70] [71] [72] . Decreased levels of circulating TSP1 in certain inbred mouse strains are also associated with increased circulating endothelial precursors and susceptibility to cancers 73 . Re-expressing TSP1 or TSP2 in cancers suppresses tumour growth and angiogenesis [74] [75] [76] [77] . Furthermore, recent evidence shows that TSP1 and TSP2 can also limit tumour growth by modulating anti-tumour innate immunity
.
The above findings have spurred efforts to identify active domains or peptides from TSP1 and TSP2 that could be developed as therapeutic inhibitors of angiogenesis and tumour growth 50, 78, 79 . A peptide sequence in the anti-angiogenic type 1 repeats of TSP1 was used to design the TSP1 mimetic ABT-510 (Ref. 80) . This drug showed efficacy for cancer therapy in animal models and recently completed two Phase II clinical trails 81, 82 . ABT-510 also synergizes with chemotherapy in murine models 83 , which prompted the initiation of combination trials for cancer [84] [85] [86] . Despite clear evidence that TSP1 potently inhibits angiogenesis in vivo, relatively high concentrations of TSP1 are typically required to inhibit endothelial cell proliferation and migration in vitro 87, 88 . One reason for this discrepancy is the absence of NO in such assays. TSP1 becomes a 100-fold more potent inhibitor in the presence of exogenous NO 18 . NO-stimulated vascular cell outgrowth into a three-dimensional collagen matrix is dramatically greater in skeletal muscle explants from Thbs1-null mice than in those from wild-type mice. As little as 10 pM TSP1 blocks NO-stimulated increases in dependence. The kinase Src, which is activated by VEGFA, also activates NOS3 through two mechanisms: phosphorylation of Tyr83 (Ref. 159) , and phosphorylation of heat shock protein 90 (HSP90), which then binds to NOS3 and activates NO synthesis 160 . Simultaneously, VEGFR2 signalling through phospholipase-Cγ (PLCγ) mobilizes intracellular Ca
2+
, which further activates NOS3 in a calmodulin (CaM)-dependent manner, and increases AMP kinase (AMPK)-mediated NOS3 phosphorylation at Ser1177 (Ref. 161) . NO produced by NOS3 binds to the prosthetic haem on soluble guanylate cyclase (sGC) to stimulate cyclic GMP synthesis, activating cGMP-dependent protein kinase (cGKI) and cGMP-gated channels to regulate downstream targets that increase endothelial cell proliferation, migration, survival and permeability 14 . Additional parallel signalling through Src, Akt and the protein kinase C-MAPK pathway (PKC-RAF1-MEK-Erk) synergizes with NO-cGMP signalling to support each of these endothelial cell responses. In vascular smooth muscle cells (VSMCs) and platelets the same downstream pathways are activated by exogenous NO diffusing from endothelium. IP 3 , inositol 1,4,5-trisphosphate; TSAd, T-cell-specific adapter protein.
Acetylcholine
A neurotransmitter in the autonomic nervous system that activates NOS3 in endothelial cells by increasing cytoplasmic calcium levels.
α-Granule
A major secretory organelle in platelets. The primary source for purification of thrombospondin 1.
Innate immunity
Cells and mechanisms that defend the host from pathogens or tumours in a non-specific manner. Innate anti-tumour immunity involves primarily macrophages and natural killer cells.
Corneal angiogenesis
The corneal angiogenesis assay is a standard method to assess pro-and anti-angiogenic factors by implanting slow-releasing polymer pellets containing the factors into the avascular cornea, usually of mice, rats or rabbits.
primary murine and human endothelial cell proliferation, matrix adhesion and migration. This concentration is lower than that found in plasma 52 , indicating that circulating TSP1 levels are sufficient to limit physiological NO-cGMP signalling in endothelium.
Inhibition of NO signalling in other vascular cells
Inhibition of NO-cGMP signalling by TSP1 is not restricted to endothelial cells. TSP1 potently inhibits NO-cGMP signalling in VSMCs and platelets 8, 89 . As discussed below, VSMCs are an important target through which TSP1 controls tissue perfusion. By suppressing the anti-thrombotic activity of NO, the TSP1 that is released during platelet activation has an important role in haemostasis 8 . By contrast, TSP1 cannot regulate cGMP synthesis in most tumour cell lines 90 , suggesting that inhibition of NO-cGMP signalling by TSP1 is specific to vascular cells.
TSP1 receptors that inhibit NO signalling
Two receptors (CD36 and CD47) mediate TSP1 inhibition of NO-cGMP signalling (fIG. 2) . Vascular cells express at least nine TSP1 receptors 91 
, but initial studies focused on CD36 for inhibiting angiogenesis. Chemotaxis of CD36-deficient endothelial cells and corneal angiogenesis in CD36-null mice were resistant to inhibition by TSP1 (RefS 92,93) . Re-expression of CD36 in the endothelial cells restored inhibition by TSP1, indicating that this activity of TSP1 requires CD36 binding. Recombinant type 1 repeats of TSP1 that engage CD36, synthetic peptides derived from these and some CD36 antibodies mimic TSP1 to inhibit angiogenesis 79, 92 . Consistent with these results, the same agents inhibited NO-stimulated responses in vascular cells 8, 18, 89 . Thus, engaging CD36 is sufficient to inhibit NO-cGMP signalling. However, TSP1 remains a potent inhibitor of NO signalling in vascular cells lacking CD36 (Ref. 94) . Therefore, CD36 is not necessary for TSP1 to inhibit NO-cGMP signalling. The corneal angiogenesis assay may overemphasize the role of CD36 owing to the high concentrations of soluble VEGF receptor 1 (VEGFR1) that block VEGFA signalling through NO in this tissue 95 . Recent evidence suggests that the potent anti-angiogenic activity of ABT-510 may also be independent of CD36 CD47 is the necessary receptor, based on the absence of TSP1 inhibitory activity in vascular cells from Cd47-null mice 94 . TSP1 engages CD47 through its carboxyterminal domain 97 , and recombinant C-terminal domain and related CD47-binding peptides potently inhibit NO signalling 94 . Thus, TSP1 blockade of physiological NO signalling in vascular cells requires CD47. CD36 engagement is sufficient to activate the inhibitory signal, but only in cells that also express CD47 (Ref. 94 ). 
Signature domain
Conserved C-terminal region of thrombospondins that includes eGf-like repeats, Ca 2+ -binding repeats and the C-terminal globular domain. In TSP1 it contains the binding site for CD47.
Partial fixed ischaemia
A partial but sustained loss of tissue blood flow.
Total ischaemia
A sustained total loss of tissue blood flow.
Furthermore, 100-fold lower concentrations of TSP1 are sufficient to inhibit vascular cell NO signalling through CD47 versus CD36 (fIG. 2) . The physiological importance of endogenous TSP1-CD47 signalling is shown by the increased basal cGMP levels in vascular cells and muscle tissue from Thbs1-and Cd47-null mice, which Cd36-null cells lack 94, 98 . TSP1 inhibits NO signalling at multiple levels sGC is clearly one target of inhibitory TSP1 signalling through CD47 (RefS 91, 99) (fIG. 2) . In addition to activation by NO binding to its haem moiety, sGC can be activated by post-translational modifications, drugs and interactions with activating proteins 100 , but the signal transduction pathway through which CD47 ligation by TSP1 inhibits sGC activation is currently unknown. It will be important to determine whether this inhibitory signalling extends to pharmacological activators of sGC to assess whether pathological increase of TSP1 levels would obviate the activity of the sGC-activating drugs currently under development for treating cardiovascular diseases associated with NO insufficiency 101 . Remarkably, TSP1 also inhibits functional responses driven by 8Br-cGMP, a cell-permeable analogue of cGMP, including a delay in platelet aggregation 18 . TSP1 inhibits 8Br-cGMP-stimulated phosphorylation of platelet vasodilator-stimulated phosphoprotein at Ser239, a direct target of cGMP-dependent protein kinase (cGK) 102 . 8Br-cGMP-induced phosphorylation of a defined cGK peptide substrate in platelet lysates is inhibited by pretreatment of platelets with TSP1. Therefore, cGK is a second target of inhibitory TSP1 signalling (fIG. 2) .
Further studies revealed a third site at which TSP1 controls physiological NO signalling. Extracellular myristate stimulates NOS3 activity in a CD36-and AMP kinase-dependent manner 103 (fIG. 2) . CD36 is a known transporter of free fatty acids 104 , and TSP1 and a CD36 antibody that mimics its anti-angiogenic activity potently block radiolabelled myristate uptake through CD36 into endothelial cells 105 . TSP1 blocks myristatestimulated cGMP synthesis in a NOS3-dependent manner. Thus, inhibition of myristate uptake through CD36 and consequent blocking of NOS3 activation is a third mechanism by which TSP1 limits NO-cGMP signalling in vascular cells (fIG. 2) . Because 1-10 nM TSP1 is required to inhibit myristate uptake whereas 10 pM TSP1 is sufficient for blocking sGC and cGK activation through CD47, sGC and cGK should be the dominant targets for cell-autonomous inhibition of NO signalling. However, the ability to inhibit endothelial NO synthesis through CD36 provides a mechanism by which circulating TSP1 could also limit the paracrine effects of endothelium-produced NO on platelets and VSMCs (fIG. 1a) .
Do other TSPs inhibit NO-cGMP signalling?
Given the potent and redundant regulation of vascular NO-cGMP signalling by TSP1, it is important to know whether this activity is shared by other members of the TSP family. All five TSPs have conserved sequence motifs in their C-terminal G module that are known to bind to CD47 as synthetic peptides 106 ( fIG. 2) , and one study provided correlative evidence that both TSP1 and TSP2 regulate inflammatory responses through CD47 (Ref. 107) . However, we found that the C-terminal signature domains of TSP2 and TSP4 bind much less avidly to CD47-expressing cells than does the signature domain of TSP1 (Ref. 108) . Consistent with their decreased binding avidities, the signature domains of TSP2 and TSP4 are less active for inhibiting NO-stimulated cGMP synthesis in vascular cells. Therefore, potent antagonism of NO signalling is relatively specific for TSP1. As discussed below, this selectivity is reflected in several phenotypes of Thbs1-versus Thbs2-null mice.
TSP1 acutely regulates blood flow
The ability of TSP1, through CD47, to block NO-stimulated relaxation of contracting VSMCs in vitro 89 translates directly to regulation of blood flow in vivo. Challenging Thbs1-or Cd47-null mice with NO results in twice the increase in regional blood flow observed in wild-type animals 7 . Thus, endogenous TSP1 engaging CD47 constantly limits the dynamic blood flow response of healthy tissue to NO.
Antagonism of NO-cGMP signalling by TSP1 becomes more pronounced under ischaemic conditions. This is relevant to cancer because of the transient and persistent hypoxic conditions found in solid tumours 109 . Ischaemic soft tissue survival and blood flow are significantly enhanced in mice lacking TSP1 or CD47. This is true for partial fixed ischaemia models using skin flaps or femoral artery ligation in hindlimbs and for total ischaemia in full-thickness skin grafts 7, 110, 111 . Conversely, loss of tissue blood flow and
Box 1 | Expanding the role of TSP1 in cancer to innate immunity
In addition to suppression of angiogenesis and acute blood flow regulation, downregulation of thrombospondin 1 (TSP1) and TSP2 during tumour progression and inhibition of growth by re-expression of the proteins in murine models can also result from modulation of innate anti-tumour immunity 137 . Overexpression of TSP1 in melanoma cells causes delayed growth and increased tumour-associated macrophage (TAM) recruitment into xenograft tumours grown in nude mice 74 . However, TAM can differentiate into either cytotoxic (M1) or tumour growth-promoting (M2) states. Increased inducible nitric oxide synthase (iNOS, also known as NOS2) is a hallmark of M1 macrophages 138 and, although M1 cytotoxic macrophages are a minor fraction of the TAM in MDA-MB-435 tumours, their recruitment or differentiation is increased when those tumours express TSP1. In vitro, TSP1 acutely induces expression of plasminogen activator inhibitor 1 (PAI1), an important regulator of macrophage migration 139, 140 , by human and mouse macrophages. PAI1 is strongly expressed by TAM in TSP1-overexpressing tumours in vivo, suggesting that TSP1-induced macrophage recruitment is at least partially mediated by PAI1 (Ref. 137) . Moreover, TSP1 and TSP2 cause a significant increase in phorbol ester-mediated superoxide generation by M1-differentated human monocytic cells, which mediates tumour cell killing, by interacting with α6β1 integrin through their amino-terminal domains. TSP1 stimulates killing of breast carcinoma and melanoma cells by M1-polarized macrophages in vitro through this release of reactive oxygen species. Taken together, these data suggest that TSP1 has an important role in innate anti-tumour immunity by enhancing the recruitment and activation of M1 TAM. Thus, avoiding this innate immune surveillance could provide an additional selective pressure for loss of TSP1 and TSP2 expression during tumour progression. 108 , further indicating that this is a specific function of TSP1.
Reperfusion of ischaemic tissue results in an additional stress mediated by the recruitment and activation of immune inflammatory cells. These in turn release inflammatory mediators and reactive oxygen species, yielding an ischaemia-reperfusion injury 112 . Increasing NO decreases ischaemia-reperfusion injury by improving return of blood flow and limiting inflammatory cell activation. Following liver ischaemiareperfusion injury, Thbs1-and Cd47-null mice show better preservation of liver cytoarchitecture and lower serum levels of released liver enzymes than wild-type mice 113 . Furthermore, pretreating wild-type animals with a function-blocking CD47 antibody decreases liver ischaemia-reperfusion injury. Therefore, endogenous TSP1 augments both fixed ischaemic and ischaemia-reperfusion injury responses. As solid tumours are constantly subjected to cycles of ischaemia and reperfusion 109 , the loss of TSP1 expression in some tumours could offer a selective advantage by maximizing the anti-inflammatory activity of the NO produced in the tumour.
Selective pressure for loss of TSP1 in cancer?
Although TSP1 clearly has acute effects on tissue perfusion in addition to its long-term regulation of angiogenesis, it was unclear whether such acute regulation extends to blood flow in tumours. On the one hand, the tumour vasculature is anatomically abnormal 114 . The tortuous channels and poor organization of tumour vasculature create turbulent flow and transient interruptions in perfusion, both of which increase overall resistance and limit the degree to which flow could increase in response to dilation of arteries and arterioles feeding the tumour vascular bed. The characteristic leakiness of tumour vasculature also results in increased interstitial pressure 115 , which further limits the ability of tumour perfusion The residues highlighted in yellow in these peptides are conserved across all five TSPs, but studies using recombinant domains of TSP2 and TSP4 indicate that high-affinity binding to CD47 is specific to TSP1 (Ref. 108 ). Binding of TSP1 or the peptides signals through CD47 to inhibit both NO-mediated activation of soluble guanylate cyclase (sGC) in endothelial cells, vascular smooth muscle cells and platelets, and cGMP-mediated activation of cGMP-dependent protein kinase (cGKI) in platelets. At high levels, TSP1 also interacts with CD36 through its central type 1 repeats and thereby inhibits its fatty acid translocase activity 105 , limiting myristate uptake into the cytoplasm and thereby inhibiting membrane translocation of Src family kinases in endothelial cells. CD36-dependent myristate uptake activates two known NOS3 (endothelial NO synthase) kinases -Src and AMP-activated protein kinase (AMPK) 96, 103 -but the relative importance of these two pathways in controlling NOS3 activation through CD36 has not been established. The TSP1 mimetic drug ABT-510 also binds to CD36 and inhibits angiogenesis through both translocase-dependent and caspase-dependent mechanisms 96, 162 . Vascular endothelial growth factor receptor 2 (VEGFR2) signalling through PI3K and phospholipase-Cg also contributes. CaM, calmodulin; EGF, epidermal growth factor; HSP90, heat shock protein 90; VEGFA, vascular endothelial growth factor A.
Hyperthermia therapy
The use of heat to damage or kill cancer cells and to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs.
BOLD-MRI
(Blood oxygen level-dependent magnetic resonance imaging). An imaging technique that assesses blood oxygenation by detecting oxygen bound to haemoglobin.
to increase in response to increased pressure in the perfusing vessels following upstream vasodilation by NO.
An ability to acutely regulate the perfusion of tumours is desirable for cancer treatment, for example to enhance hyperthermia therapy by decreasing tumour blood flow or to increase intravenous delivery of cytotoxic therapeutics by increasing flow. In many but not all tumours, vasodilators such as NO diminish flow through the tumour and vasoconstrictors increase flow 116, 117 . This paradoxical outcome has given rise to the concept of a 'vascular steal phenomenon' 118 , which is based on evidence that vessels in healthy tissue are more responsive to vasoactive agents than are vessels in the tumour (fIG. 3a) . Thus, systemic vasodilation would 'steal' blood flow from the tumour by selectively decreasing resistance in the healthy tissues.
We recently examined the ability of TSP1 to acutely regulate tumour blood flow using syngeneic melanomas grown in wild-type and Thbs1-null mice 90 . Blood flow in tumour versus normal tissue was imaged using BOLD-MRI. Consistent with BOlD-MRI data in healthy mice at rest 7 , flow through normal soft tissue increased when tumour-bearing mice were challenged using a rapidly releasing NO donor, and the increase was greater in Thbs1-null mice. By contrast, flow through the tumour decreased immediately after NO challenge and did not differ between the Thbs1-null and wild-type mice. This decrease in tumour flow is consistent with a steal effect, indicating that the tumour vasculature is less able to acutely dilate in response to NO. Because tumours in wild-type and Thbs1-null mice showed similar resistance, this inability to respond to NO is not dependent on TSP1 expression in the tumour vasculature. Therefore, the tumour vasculature has a limited ability to acutely alter its perfusion, due to either its abnormal vascular architecture or an absence of functional smooth muscle 119 . Rather, vasoactive agents indirectly alter tumour perfusion by either increasing or decreasing the hydrostatic pressure in major vessels supplying the tumour (fIG. 3a) .
Acute flow changes following vascular challenge were also examined in a melanoma xenograft model 90 . The parental melanoma cell line MDA-MB-435 lacks significant TSP1 expression and is tumorigenic in athymic mice 74 . As with the syngeneic melanoma, NO challenge decreased flow through this xenograft tumour while increasing flow in the contralateral leg, and injection of the vasoconstrictor adrenaline increased flow through the tumour while decreasing flow elsewhere. However, when the same tumour cells were engineered to express TSP1, which decreases growth, angiogenesis and spontaneous lung metastasis 74 , the acute decrease in flow following NO challenge was diminished, and adrenaline challenge did not increase flow. Therefore, TSP1 secretion by a tumour can limit its acute responsiveness to blood flow regulation. This could involve local effects of TSP1 on the tumour vasculature, but a more likely explanation is that TSP1 released into the circulation from the tumour tempers acute responses of vascular beds outside of the tumour to vasodilator or vasoconstrictor challenge (fIG. 3b) .
The concept that TSP1 can temper acute regulation of tumour blood flow has several implications. Although TSP1 expression is frequently suppressed in tumours, increased circulating TSP1 levels derived from stromal cells have been reported in certain human cancers 11, 12 . Our data suggest that such increased circulating TSP1 could increase tumour perfusion if it selectively vasoconstricts and thereby limits the perfusion of healthy tissues. This hypothesis is consistent with the known ability of endogenous TSP1 to limit blood flow through normal muscle and in ischaemic tissues 7 . A second implication of this data concerns the use of angiogenesis inhibitors in conjunction with chemotherapy or radiotherapy. To enhance radiotherapy and chemotherapy responses, agents have been sought that temporarily increase tumour perfusion. Our results suggest that a TSP1 mimetic administered before irradiation could temporarily increase tumour perfusion and thereby enhance responses to radiotherapy. Similarly, TSP1 mimetics could improve tumour delivery of chemotherapeutics by selective vasoconstriction of extratumoural vessels (fIG. 3b) . However, such mimetics should be used with caution since they would be expected to also have similar prothrombotic activity to TSP1 (Ref. 8.) Indeed, we found that ABT-510 is a weak inhibitor of myristate uptake through CD36 (fIG. 2) , and ABT-510 has corresponding pro-thrombotic activities in platelets 96 and some patients 86 .
Do therapeutic inhibitors resemble TSP1?
Analogous to TSP1 and ABT-510, the hypertensive activity of therapeutic angiogenesis inhibitors may contribute to their efficacy. Bevacizumab, sunitinib and sorafinib block VEGFA-dependent activation of NOS3 (fIG. 4) . In addition to inhibiting NO-cGMP signalling in endothelial cells, these inhibitors decrease the flux of NO released by endothelial cells to act on other vascular targets. This can explain the acute regulation of blood pressure by intravenous VEGFA and cediranib 6 .
Box 2 | TSP1 receptors that regulate angiogenesis
Although intact thrombospondin 1 (TSP1) is a potent angiogenesis inhibitor, its amino-terminal domains have pro-angiogenic activities 141, 142 . These are mediated by interactions with several TSP1-binding integrins: α3β1, α4β1, α6β1 and α9β1 (RefS 141, (143) (144) (145) . The N-terminal domain of TSP1 also modulates endothelial cell focal adhesions and vascular permeability by engaging calreticulin and low-density lipoprotein receptor-related protein 1 (LRP) 146, 147 . The central type 1 repeats of TSP1 and TSP2 inhibit angiogenesis by engaging the receptor CD36 (RefS 92,148) . CD36, a class B scavenger receptor and fatty acid translocase 104 , is expressed on microvascular endothelium and vascular smooth muscle cells. Peroxisome proliferator-activated receptor-γ (PPARγ) ligands increase vascular expression of CD36 and correspondingly increase tumour responses to the CD36-targeted drug ABT-510 (Ref. 149) . A coding polymorphism in CD36 was associated with increased risk of colorectal carcinoma in a Japanese population 150 . CD47 is a high-affinity cell surface receptor for the carboxy-terminal domain of TSP1 and a low-affinity receptor for this domain of TSP2 (Ref. 108) , but the specific residues in TSP1 that mediate binding to CD47 are currently a subject of debate [151] [152] [153] . CD47 is ubiquitously expressed and also has an important role in regulating phagocytosis through engaging its counter-receptor, SHPS1 (Ref. 154) . In breast cancer and some haematological malignancies, antibody targeting of CD47 can kill tumour cells 155, 156 . 
Wet desquamation
Skin damage leading to broken skin or infection due to a fluid-filled abscess created by blocked ducts or capillaries, which is a characteristic side effect of high-dose irradiation.
By analogy, we argue that the pro-thrombotic and hypertensive activities reported for clinical angiogenesis inhibitors have a similar basis (fIG. 4; TABLe 2). A similar explanation was recently proposed for the renal side effects of these drugs 120 .
TSP1 and cancer evolution
The increased circulating TSP1 levels that are typical of certain cancers may provide a selective advantage to the tumour by maximizing tumour perfusion at the expense of other vascular beds. If circulating TSP1 in cancer does serve to increase perfusion of the tumour, could the discovery of other circulating angiogenesis inhibitors such as endostatin 9 , which inhibits NOS3 activation through the phosphatase PP2A 121 and inhibits sGC expression 122 (fIG. 4) , indicate that their release into the host circulation generally confers an advantage to the tumour by increasing perfusion? This could be viewed as a competitive evolutionary adaptation of tumours to maximize the nutrients they can obtain 123 . Conversely, platelet interactions with tumour cells have a crucial role in metastasis 124 , so the ability of TSP1 to increase platelet adhesion 8 could provide a selective advantage that would account for the observed increased metastatic spread of some tumours that induce higher levels of circulating TSP1 (Ref. 125) . Both of these hypotheses merit further study to define what selective pressures drive these changes in TSP1 expression.
TSP1 and radiosensitivity
Angiogenesis inhibitors are increasingly being tested in combination with radiotherapy. Empirical evidence from animal tumour models and human clinical trials indicates that this combination is beneficial 126 , but the mechanism remains controversial. On the one hand, tumours have hypoxic regions and, based on their ability to normalize the tumour vasculature, angiogenesis inhibitors may improve the overall oxygenation of tumours in an NO-dependent manner 127 . Increased tissue oxygenation can increase radiosensitivity 109, 128 . This scenario predicts that prior treatment with angiogenesis inhibitors would produce the best enhancement. On the other hand, some studies have shown enhanced radiosensitivity when angiogenesis inhibitors are administered either immediately before or after irradiation 129 . In this case, mechanisms other than vascular normalization must account for their efficacy. On the basis of the radioresistance of tumours grown in mice lacking BAX or sphingomyelin phosphodiesterase, which protect the tumour vasculature from radiation-induced apoptosis, tumour endothelial cells were proposed to be the crucial radiosensitive component of tumours 130 . Thus, combining angiogenesis inhibitors with radiation could increase apoptosis within the tumour vasculature and thereby starve the tumour of nutrients. This could account for some acute radiosensitization by angiogenesis inhibitors. However, other studies have questioned the limiting role of tumour vasculature in tumour radioresistance 131, 132 .
Given the many variables that can influence tumour tissue responses to radiation, it is important to first understand how angiogenesis inhibitors influence radio sensitivity in normal tissue. In addition to shedding light on cancer radiosensitivity, any manipulation that improves the radioresistance of normal tissue could be exploited to locally protect surrounding healthy tissue and thereby maximize the radiation dose that can be delivered to an underlying tumour. If tumour radiosensitivity indeed proves to be more important than that of the tumour vasculature, systemic administration of a vascular radioprotectant could prevent radiation damage to healthy tissue without compromising tumour ablation.
Assessing the radiosensitivity of healthy soft tissue in mice, we recently found that Thbs1-null mice are remarkably resistant to high-dose (25 Gy) hindlimb irradiation 133 . In the skin, alopecia and wet desquamation were lower than that observed in wild-type mice, and histological examination after 2 months confirmed the preservation of skin architecture and function. Remarkably, underlying skeletal muscle in Thbs1-null mice showed essentially no signs of necrosis or fibrosis following irradiation. Not only was muscle mitochondrial function preserved, but the Thbs1-null mice tended to have greater muscle mass in the irradiated hindlimb compared with non-irradiated control limbs. Responses to irradiation in Cd47-null mice paralleled those of Thbs1-null mice, indicating that this TSP1 receptor is crucial to the radiosensitizing activity of endogenous TSP1. Thbs2-null mice showed no protection from radiation injury, however, indicating that this activity is specific for TSP1.
Shortly after irradiation, apoptosis was also decreased in the muscle and bone marrow of Thbs1-and Cd47-null mice. Because CD47 and TSP1 are also implicated in the recruitment of inflammatory cells at sites of infection or injury 97, 134 , we considered whether the apparent radioprotection could be secondary to a decreased inflammatory response in the irradiated Thbs1-and Cd47-null limbs. To eliminate this variable, radiosensitivity was assessed in vascular cells isolated from the respective mice. Remarkably, Thbs1-and Cd47-null cells in culture replicated the radioresistance of their hosts 133 . The Thbs1-and Cd47-null cells exhibited less death following irradiation and, over time in culture, maintained the proliferative capacity that was progressively lost by irradiated wild-type cells. Thus, eliminating the signal from secreted TSP1 engaging its receptor CD47 dramatically protects the viability and proliferative capacity of cells after highdose irradiation. Cell-autonomous radioprotection in the Thbs1-and Cd47-null cells indicates that blocking this pathway in vivo could be protective, independently of any effect of these proteins on the immune system. Although increasing NO levels is known to be radioprotective for whole-body irradiation 135 , ongoing experiments indicate that regulation of NO-cGMP signalling only partially explains this radioprotection. Additional molecular mechanisms are under investigation.
Returning to the controversy concerning the relative contributions of tumour cells versus host vasculature to radiosensitivity, we compared regrowth delays after irradiation of syngeneic B16 melanomas implanted in wild-type versus Thbs1-null mice 133 . No decrease in regrowth delay was observed in the Thbs1-null mice. Therefore, antagonists of TSP1-CD47 interaction merit testing as selective radioprotectants and could permit higher radiation doses to be delivered to tumours while preserving the functions of crucial adjacent tissues and organs. The current US Food and Drug Administration-approved angiogenesis inhibitors for cancer therapy block vascular endothelial growth factor A (VEGFA) binding to VEGF receptor 2 (VEGFR2) -the inhibitor bevacizumab -or inhibit the tyrosine kinase activity of VEGFR2 -the inhibitors sorafenib and sunitinib. VEGFR2 activates several parallel signalling pathways that control angiogenesis, but inhibiting NO-cGMP signalling blocks most of these responses. Therapeutic responses to VEGFA inhibitors may be limited by parallel activation of the downstream pathways by additional angiogenic factors produced by tumours that can activate NO-cGMP signalling independently of VEGFR2, such as adrenomedullin, angiopoietin 1, sphingosine 1-phosphate (S1P), lysophosphatidic acid (LPA), angiopoietin-related growth factor (AGF), oestrogens, insulin and fibroblast growth factor 2 (FGF2) 15, [22] [23] [24] . Therefore, inhibitors that act on essential downstream pathways may be more effective than the existing VEGFA-VEGFR2 antagonists for controlling tumour angiogenesis. Endostatin is one such agent that acts through the phosphatase PP2A to inhibit endothelial NO synthase (NOS3) activation 121 and downstream to inhibit soluble guanylate cyclase (sGC) expression 122 . Thrombospondin 1 (TSP1) is a redundant inhibitor of the NO-cGMP cascade, and the experimental drug ABT-510, a TSP1 mimetic, inhibits angiogenesis through the TSP1 receptor CD36 (Ref. 96) . However, native TSP1 also acts through the more potent inhibitory pathway mediated by CD47. Pro-angiogenic factors and signalling pathways are shown in green, and anti-angiogenic factors and pathways are in red. cGK, cGMP-dependent protein kinase; HSP90, heat shock protein 90; PLCγ, phospholipase-Cγ.
Conclusions and perspectives
Several common themes are emerging from studies of the endogenous inhibitor TSP1 and therapeutic angiogenesis inhibitors. First, we must not allow the name angiogenesis inhibitor to limit how we view the physiological pathways influenced by these agents. NOcGMP signalling is an important component of proangiogenic signalling downstream of VEGFA and other vascular growth factors, but the same pathway also mediates acute effects of VEGFA signalling on vascular smooth muscle tone and regulates platelet homeostasis (fIG. 4) . Just as VEGFA has both long-term and acute effects on vascular physiology and thrombosis, endogenous and therapeutic angiogenesis inhibitors should be expected to acutely affect the same pathways. TSP1 is an acute vasoconstrictor 136 , and bevacizumab and VEGFR kinase inhibitors exhibit similar hypertensive activities. TSP1 and the therapeutic Vegf pathway antagonists also share similar pro-thrombotic activities. Because NO rapidly diffuses between cells, blocking NO synthesis by endothelial cells using Vegf pathway antagonists lowers the level of NO seen by platelets and VSMCs.
This concept is beginning to be recognized in attempts to overcome the side effects of therapeutic Vegf antagonists 6 . If NO-cGMP signalling is crucial for both angiogenesis and acute cardiovascular regulation, then manipulation of other pathways unique to acute vascular regulation may compensate for loss of NO signalling. Thus, use of antihypertensive drugs (an angiotensinconverting enzyme inhibitor or a calcium channel blocker) overcame the hypertensive activity of cediranib without blocking its inhibition of tumour growth 6, 120 . What does this teach us about designing a better angiogenesis inhibitor? One scenario would be to selectively target components of the NO-cGMP signalling cascade that mediate long-term regulation of angiogenesis but not acute cardiovascular responses. The current Food and Drug Administration-approved angiogenesis inhibitors all are expected to inhibit NOS3 activation and thus lower the level of NO available for its paracrine regulation of VSMCs and platelets. TSP1 signalling through CD47 inhibits sGC and cGK activation. Drugs that selectively inhibit at this level in endothelium could potentially block the autocrine pro-angiogenic activity of NO without blocking physiological NO paracrine signalling to the underlying VSMCs. Antibodies that engage CD47 and mimic TSP1 binding would be one such approach. These would engage CD47 on the endothelium but be too large to cross the basement membrane to inhibit signalling in the VSMCs. CD47 antagonists may also provide an advantage over VEGFA antagonists by their ability to also block the NO-cGMP signalling that is induced by other tumour-derived angiogenic factors (fIG. 4) .
As we learn more about the specific downstream targets of NO-cGMP signalling that are crucial for longterm angiogenic responses versus acute vasoregulation and haemostasis, additional targets may be identified that can selectively block the pro-angiogenic aspects of NO-cGMP signalling. Achieving this goal will require further efforts to map the signalling networks mediating acute and chronic responses to NO in each vascular cell type.
Studies of TSP1 are also teaching us that angiogenesis inhibitors can profoundly affect other aspects of tumour biology including anti-tumour immunity and radiotherapy responses. Although TSP1 potently inhibits NO-cGMP signalling, additional signalling pathways controlled by TSP1 may be important for these other activities. Investigating these may identify additional targets for controlling tumour growth and improving responsiveness to ablative therapies. 
